Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone fragment ACTH(4–7), modified with a C-terminal Pro–Gly–Pro sequence to enhance metabolic stability. It was developed for experimental investigation of neuropeptide signalling, neuromodulation, and central nervous system regulatory pathways.
In biochemical and cellular research systems, Semax has been studied for its interactions with neuronal signalling pathways associated with neurotrophic factors, synaptic plasticity, and stress-response regulation. Experimental models commonly investigate its effects on intracellular signalling cascades, gene expression related to neurotrophins, and modulation of neurotransmitter systems. Observed molecular responses are dependent on experimental design, concentration, and model system.
Applications in Research
- As a molecular probe for studying neuropeptide-mediated signalling pathways.
- Investigation of neuronal plasticity, neurotrophic signalling, and stress-related molecular mechanisms.
- In vitro and in vivo research examining peptide stability and CNS-active peptide analogues.
- Use as a reference compound in neurobiology and peptide signalling research.
Specifications Summary
Purity (HPLC): ≥ 99 %
Appearance: White to off-white lyophilised powder
Molecular Weight: ~813.92 g/mol
Peptide Type: Synthetic ACTH-derived neuropeptide
Solubility: Water, buffered aqueous solutions
Storage: –20 °C, desiccated, protected from light
Pack Size: 10 mg
Precautions & Notes
- Experimental behaviour of Semax is influenced by neuronal model, receptor expression, peptide concentration, and exposure duration.
- Buffer composition, pH, and ionic strength may affect peptide stability.
- Appropriate controls are recommended to distinguish specific from non-specific effects.
- Intended strictly for laboratory research use; not for human or veterinary application.
Keywords: Semax, ACTH(4–7), Synthetic Neuropeptide, CNS Signalling, Neurotrophic Peptide
